Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Astellas Pharma : and Seattle Genetics Announce PADCEV Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

share with twitter share with LinkedIn share with facebook
09/24/2020 | 08:30am EDT

TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that a phase 3 trial of PADCEV (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy.

The results were reviewed by an independent Data Monitoring Committee following a planned interim analysis. The global EV-301 clinical trial compared PADCEV to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor.

In the trial, PADCEV significantly improved overall survival (OS), with a 30 percent reduction in risk of death (Hazard Ratio [HR]=0.70; [95% Confidence Interval (CI): 0.56, 0.89]; p=0.001). PADCEV also significantly improved progression-free survival (PFS), a secondary endpoint, with a 39 percent reduction in risk of disease progression or death (HR=0.61 [95% CI: 0.50, 0.75]; p

(C) 2020 Electronic News Publishing, source ENP Newswire


Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. -1.26% 1452.5 End-of-day quote.-22.33%
SEAGEN INC. 0.56% 196.92 Delayed Quote.71.39%
share with twitter share with LinkedIn share with facebook
All news about ASTELLAS PHARMA INC.
10:15aASTELLAS PHARMA INC. : half-yearly earnings release
10/23ASTELLAS PHARMA : ITI Announces Promotion of Dr. Tim Coleman to SVP, Operations ..
AQ
10/21ASTELLAS PHARMA INC. : - U.S. FDA Grants Fast Track Designation for ASP0367/MA-0..
AQ
10/20ASTELLAS PHARMA INC. : - New Roxadustat Data in Anemia of Chronic Kidney Disease..
AQ
10/19ASTELLAS PHARMA : China Update – Drug Patents
AQ
10/16ASTELLAS PHARMA : to acquire iota Biosciences
AQ
10/16Nikkei flat as coronavirus resurgence in Europe hits sentiment
RE
10/15ASTELLAS PHARMA : FibroGen to Present New Efficacy and Safety Analyses from Roxa..
AQ
10/15ASTELLAS PHARMA : to Acquire iota Biosciences
BU
10/13ASTELLAS PHARMA : and Seagen Announce Positive Topline Results from Second Cohor..
AQ
More news
Financials
Sales 2021 1 274 B 12 191 M 12 191 M
Net income 2021 204 B 1 954 M 1 954 M
Net cash 2021 450 B 4 304 M 4 304 M
P/E ratio 2021 13,1x
Yield 2021 2,90%
Capitalization 2 698 B 25 837 M 25 818 M
EV / Sales 2021 1,76x
EV / Sales 2022 1,57x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 275,00 JPY
Last Close Price 1 452,50 JPY
Spread / Highest target 85,9%
Spread / Average Target 56,6%
Spread / Lowest Target 17,0%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-22.33%26 055
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381